The world’s most common childhood disability, cerebral palsy, has long been associated with birth complications like premature birth, infection, lack of oxygen, and perinatal stroke. But population studies suggest those factors account for only a fraction of cases. To fill this diagnostic void, modern medicine has routinely turned to gene sequencing to hunt for a root cause, and researchers have zeroed in on certain genetic variants in a substantial subset of children with cerebral palsy.
For families, gene sequencing offers a profound hope: of ending a gruelling diagnostic odyssey. Finding a definitive genetic root cause optimises patient management, reduces unnecessary testing, and finally gives parents concrete answers.
But a new study in The American Journal of Human Genetics suggests simply finding a pathogenic gene variant in a child is not proof that it caused their motor disability.
In resource-constrained healthcare systems like India’s, acting on a false alarm from a standard genetic panel can divert already limited medical resources away from treatments that actually work.
“The medical community previously has not comprehensively examined the statistical evidence in favor of a cerebral palsy association for genes flagged in large genomics cohort studies,” Peter N. Robinson, a computational biologist at the Jackson Laboratory for Genomic Medicine, U.S., and the study’s corresponding author, said. “Our study showed that there is convincing evidence for only a subset.”
Collapsing narrative
The researchers combed through 21 previously published genomic diagnostic studies involving 5,440 individuals diagnosed with cerebral palsy. Across these diverse cohorts, the original authors had pointed the finger at a staggering 515 different candidate genes, reporting them as the direct genetic cause of the patients’ symptoms.
But when Dr. Robinson’s team subjected this historical data to rigorous statistical analysis, the established narrative collapsed. Sufficient statistical evidence could only confirm a true association for 89 of those 515 proposed genes.
Sequencing the genomes of 460 patients across the Shriners Children’s hospital network in the U.S., the team also identified disease-causing mutations in 60 genes across 15.8% of children. Yet their stricter statistical paradigm whittled the list down to only 16 with significant evidence linked to cerebral palsy.
“What this paper is trying to suggest is some of the genetic variants may not be slam dunk,” said Kuntal Sen, a clinical geneticist and paediatric neurologist at Children’s National Hospital, U.S. “It might explain one problem, like intellectual disability, but it may not tie together everything. Which is a fair point to make, that some genetic test reports might be just a slight association rather than causal.”
False alarms
These false alarms can be traced back to a few traps. One is coincidence. Because roughly 5% of the general population harbours a rare genetic disease, sequencing a child with cerebral palsy frequently uncovers severe mutations entirely unrelated to the disability.
A previous large-scale study flagged the LIPH gene as a cause of cerebral palsy because an affected patient happened to carry it. However, mutations in LIPH actually cause a rare form of hair loss and possess no known neurological link.
Conversely, across both historical literature and the newly sequenced cohort, CTNNB1 mutations showed up far more often than random chance would allow, providing the proof necessary to confirm it is a real risk factor.
The confusion is also compounded by the fact that ‘cerebral palsy’ is a clinical catch-all rather than a single biological disease.
“For me, I think the term ‘cerebral palsy’ does not always make sense from a purely scientific perspective.,” Dr. Sen said. “The motor symptoms that the children have [severe muscle stiffness, and weakness affecting either one side of the body or all four limbs] are more scientifically informative.”
He noted the outdated label survives, rightfully, mainly because it guarantees patients access to specialised insurance and physical therapy in the western world.
But as an umbrella term for brain-derived muscle weakness, the diagnosis lumps a large variety of conditions together. While some stem from birth injuries, others are ‘mimics’: rare metabolic or genetic disorders masquerading as a muscle weakness.
Stakes of precision
This heterogeneous reality is why distinguishing a harmless genetic coincidence from a true biological driver carries large stakes.
If doctors accept an incidental mutation from a standard genetic panel as the final answer, they may halt their workup prematurely, leaving a true, treatable ‘mimic’ undiscovered. But accurately pinpointing the biological cause using strict statistical proof can fine-tune this personalised approach and open the door to highly targeted care.
“If the genetic test report gives you a slam dunk answer, you counsel them, you provide management guidelines, and you can also give a recurrence risk for other family members,” Dr. Sen said.
The researchers estimated that among 8.5% to 24% of individuals who receive a valid genetic diagnosis, the findings point to specific, available treatments. By catching mimics early, doctors can swap generic physical therapy for precise interventions, such as dietary changes for arginase deficiency or specific medications for vitamin-dependent epilepsies and hereditary dystonia.
For these families, getting the statistics right means much more than simply solving a mystery. It unlocks treatments that can alter the course of a child’s life.
For countries like India, where three in every 1,000 live births are affected by cerebral palsy and genetic testing is an emerging and rapidly growing field, studies like this offer an advantage. A severe mutation that breaks a specific protein and masquerades as cerebral palsy does so universally, regardless of ethnicity. And by identifying only the true genetic mimics, local clinics can skip the diagnostic trial-and-error phase of older, bloated sequencing panels, and pave the way to adopt highly accurate genetic testing, connecting families to precise treatments faster.
Cautious path
While the Robinson et al. study has set a rigorous new standard, the authors have also conceded their strict mathematical model might actually underestimate the true number of genes linked to the disorder.
“One must remember that the lack of statistical significance does not imply the absence of an association,” Dr. obinson said. “It is very likely that there are more genes with cerebral palsy association than the 89 we flagged.”
Realising the full promise of this approach will require the medical community to move beyond just sequencing DNA. Scientists need large, globally shared datasets of detailed patient profiles to finally calculate the exact degree of risk a specific genetic variant carries.
Ultimately, translating these statistical insights into daily practice will take time. “With appropriate caution, genomic testing can be a useful addition to CP diagnostics,” Dr. Robinson said. “Caring physicians will integrate many kinds of information when making the decision.”
Anirban Mukhopadhyay is a geneticist by training and science communicator from New Delhi.
